niraparib

This page shows the latest niraparib news and features for those working in and with pharma, biotech and healthcare.

AZ and MSD surpass rivals with updated Lynparza data

Rival Tesaro is also expecting phase III results in the same setting for its PARP inhibitor Zejula (niraparib), but much like Lynparza, that data won’t be available until next year.

Latest news

NICE backs Tesaro’s Zejula via the CDF

Some ovarian cancer patients in England and Wales will soon be able to access Tesaro’s once daily, PARP Inhibitor Zejula (niraparib), following a recent approval by the National Institute of
Maintenance OK boosts AstraZeneca’s Lynparza in Europe

The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for
Maintenance OK boosts AstraZeneca’s Lynparza in Europe

The drug is the second to be approved for use in this setting after Tesaro’s PARP drug Zejula (niraparib), and ahead of another rival – Clovis Oncology’s Rubraca (rucaparib) – for
CHMP backs AZ’s Lynparza for ovarian cancer maintenance

in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib).
AZ and Merck & Co get FDA breast cancer nod for Lynparza

Johnson &Johnson/Tesaro’s Zejula (niraparib).

More from news
Approximately 3 fully matching, plus 23 partially matching documents found.

Latest Intelligence

Deal Watch April 2016

Licensing one indication for a new product is unusual not least of all because of potential pricing issues if niraparib is launched by different companies at different prices. ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer

No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer. ... The ENGOT-OV16/NOVA trial of niraparib was a randomized, double-blinded placebo study with women with relapsed platinum-sensitive high-grade ovarian cancer.

More from PMHub
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Associate Scientific Director: Salary TBC

Senior Training Manager - Surrey: Competitive Salary &Bonus

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Systematic Review Lead- London: Negotiable

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Editorial Director – Medical Education: Neg

Senior Writer, Healthcare Advertising, London: Excellent package

Account Director, Healthcare Advertising Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Account Manager- 4 days per week or full-time: Salary TBC

Graduate Scientific Editor: DOE

Senior Medical Writer: Salary is DOE

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Director or Senior Account Director: Salary TBC

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Healthcare PR Senior Account Manager: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Subscribe to our email news alerts

PMHub

Add my company

Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....